Cytochrome P450 pharmacogenetics and cancer
نویسندگان
چکیده
منابع مشابه
Priority pharmacogenetics for the African continent: Focus on Cytochrome P450
Countries in Africa have a high burden of communicable disease, and are experiencing an increase in non-communicable diseases due to the effects of globalization, industrialization and urbanization. The costs incurred through adverse drug reactions and non-responsiveness to therapy further aggravate the situation, and the application of pharmacogenetic principles is likely to provide some relie...
متن کاملClinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children
Cytochrome P450 (CYP) enzymes are commonly involved in drug metabolism, and genetic variation in the genes encoding CYPs are associated with variable drug response. While genotype-guided therapy has been clinically implemented in adults, these associations are less well established for pediatric patients. In order to understand the frequency of pediatric exposures to drugs with known CYP intera...
متن کاملPharmacogenetics of Cytochrome P450 2D6: A Translational Medicine Perspective
With rapid scientific advances in the postgenomic era, pharmacogenomics has developed into an important area of translational medicine research. Pharmacogenetics studies the variability in drug response between different patient genotypes. By using patient genomic information, this bench-to-bedside research approach aims to develop more effective targeting of drug therapy in clinical practice. ...
متن کاملPharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
BACKGROUND AND OBJECTIVES Cytochrome P4502C9 (CYP2C9) is the main enzyme implicated in coumarinic metabolism. Variant alleles, CYP2C9*2 and CYP2C9*3, have been related to decreased enzymatic activity, but their clinical relevance in acenocoumarol metabolism has not been established. We investigated CYP2C9 polymorphisms in relation to acenocoumarol dose requirement, stability of anticoagulation ...
متن کاملIntegrating Clinical Pharmacokinetics, Pharmacogenetics, and Quantitative Cytochrome P450 Polymorphic Gene Drug-Drug Interactions (DDIs).
We read the article by Deer and Gunn [March-April issue] (1) with substantial interest, and felt it might be helpful to provide readers with a quantitative viewpoint. A methodology for rational opioid dose regimen design and modification based on clinical pharmacokinetics for therapeutic drug monitoring is available (2). This methodology has been integrated with pharmacogenetics for precision m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncogene
سال: 2006
ISSN: 0950-9232,1476-5594
DOI: 10.1038/sj.onc.1209377